Clovis Oncology agreed to acquire Italy-based Ethical Oncology Science for $200 million upfront plus milestone fees. The deal gives Clovis rights to EOS' lead cancer drug candidate, lucitanib, which is in Phase I/IIa trials. "We have been interested in lucitanib for some time and are pleased to have acquired EOS to add this program to our portfolio. It is highly consistent with our focus on developing targeted therapies that provide meaningful benefit to specific patient populations," Clovis President and CEO Patrick J. Mahaffy said.
Published in Brief: